newsfilter
← Latest News
GlobeNewswire·

Annovis Announces Pricing of $21.0 Million Public Offering

MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,